This is a rare type of lymphoma that starts in the fluid around the lungs, heart, or abdomen. It's not usually found as a solid lump, but instead causes these fluids to build up. It's often linked to a specific virus and can happen when your immune system is weak.
Every report comes from a Lived member, sent anonymously.
Have you had Chemotherapy infusion for Primary Effusion Lymphoma?
Primary effusion lymphoma (PEL) is a rare, fast-growing cancer of B cells, a type of white blood cell. Unlike most lymphomas, which form lumps in lymph nodes, it usually grows as lymphoma cells floating in fluid that builds up in the body's natural cavities: the space around the lungs, the abdomen or the sac around the heart. A buildup of fluid like this is called an effusion, and there is typically no solid tumor to find. Because the problem is fluid, the symptoms depend on where it collects. Fluid around the lungs causes shortness of breath, fluid in the abdomen causes swelling and fullness, and fluid around the heart can squeeze it and lower blood pressure. Many people also have fever, night sweats and weight loss. A less common form, called extracavitary PEL, appears as a solid mass in lymph nodes or organs such as the gut, lungs or skin instead of as fluid.
PEL is caused by human herpesvirus 8 (HHV-8), also called Kaposi sarcoma herpesvirus because it also causes Kaposi sarcoma. In people with a healthy immune system, the body keeps this virus in check. PEL develops mainly when the immune system is weakened and can no longer control the infected cells. Most tumors also carry Epstein-Barr virus, though it is not thought to be required for the cancer to form. In the United States, PEL appears in two main groups. The first is younger adults with HIV, usually men, especially those with advanced immune damage or a past diagnosis of Kaposi sarcoma. The second is older adults without HIV, including people from regions where HHV-8 is common and people taking immune-suppressing medicines after an organ transplant. Carrying HHV-8 does not mean a person will develop PEL; the cancer is uncommon even among people with the virus.
The diagnosis comes from the fluid itself. A doctor uses a needle to draw off some of the effusion (from around the lung, the abdomen or the heart), which can also ease symptoms. A pathologist then examines the cells under a microscope and runs stains to identify them. The key confirming test shows HHV-8 inside the lymphoma cells. This matters because PEL cells look unusual and can resemble other lymphomas or cancers that spread to the lining of the lungs. Other tests help plan treatment. Imaging such as a CT or PET scan looks for fluid in other cavities and for any solid masses. Blood tests check blood counts, organ function and, for people with HIV, the CD4 count (a measure of immune strength) and HIV viral load. Knowing whether a person has HIV matters, because it shapes treatment.
There is no single standard treatment, because PEL is too rare for large comparative trials. Most people who are fit enough receive combination chemotherapy of the kind used for other aggressive lymphomas, such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or dose-adjusted EPOCH, which adds etoposide and adjusts doses to blood counts. Chemotherapy can put PEL into remission, meaning no detectable cancer, though it does so less reliably than in more common lymphomas. Rituximab, an antibody that helps many B-cell lymphomas, usually has a limited role here because PEL cells generally lack the CD20 marker it targets. For people with HIV, antiretroviral therapy is continued or started alongside chemotherapy to help the immune system recover. Care works best with a cancer specialist and an HIV specialist together, since some HIV medicines interact with chemotherapy and may need to be changed. Treatment also usually includes medicines to prevent infections such as pneumonia and to support white blood cell counts. Draining fluid relieves breathing or abdominal symptoms, and if fluid around a lung keeps returning, a procedure called pleurodesis can seal the space. For PEL that returns after treatment, options may include stem cell transplant, CAR T-cell therapy (which uses a person's own immune cells, modified in a lab to attack the lymphoma) or a clinical trial. Older people or those too unwell for intensive chemotherapy may receive gentler treatment focused on comfort and control of symptoms.
PEL is a serious cancer, and outcomes have historically been poor, with many people living less than a year after diagnosis. The picture is not the same for everyone, however. In recent studies of people with HIV treated with chemotherapy, those who were still largely able to care for themselves and did not have severe anemia often lived for many years, while those who were very unwell at diagnosis did much worse. Fluid in more than one cavity and certain blood markers are also linked to a harder course. Treatment usually means several months of chemotherapy cycles, often given in the hospital or infusion clinic, with frequent blood tests. Fatigue, low blood counts and a higher risk of infection are common during this time. People with HIV take antiretroviral therapy throughout. After treatment ends, regular visits and scans check for any return of fluid or lymphoma.
See a doctor about fluid buildup that keeps coming back, unexplained swelling of the abdomen, or ongoing fever, night sweats and weight loss, especially if you have HIV, a history of Kaposi sarcoma or an organ transplant. During treatment, call your care team right away for a fever of 100.5°F (38°C) or higher or shaking chills, since chemotherapy weakens defenses against infection. Call 911 for sudden or severe trouble breathing, chest pain, fainting or a racing heartbeat, which can signal fluid pressing on the heart.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Primary Effusion Lymphoma is like, what's helped you, or ask the community a question.